Metabolically defined body size and body shape phenotypes and risk of postmenopausal breast cancer in the European Prospective Investigation into Cancer and Nutrition.
body mass index
breast cancer
concentrations of C-peptide
metabolic health
waist circumference
waist-to-hip ratio
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
revised:
06
03
2023
received:
24
10
2022
accepted:
23
03
2023
medline:
20
6
2023
pubmed:
25
4
2023
entrez:
25
04
2023
Statut:
ppublish
Résumé
Excess body fatness and hyperinsulinemia are both associated with an increased risk of postmenopausal breast cancer. However, whether women with high body fatness but normal insulin levels or those with normal body fatness and high levels of insulin are at elevated risk of breast cancer is not known. We investigated the associations of metabolically defined body size and shape phenotypes with the risk of postmenopausal breast cancer in a nested case-control study within the European Prospective Investigation into Cancer and Nutrition. Concentrations of C-peptide-a marker for insulin secretion-were measured at inclusion prior to cancer diagnosis in serum from 610 incident postmenopausal breast cancer cases and 1130 matched controls. C-peptide concentrations among the control participants were used to define metabolically healthy (MH; in first tertile) and metabolically unhealthy (MU; >1st tertile) status. We created four metabolic health/body size phenotype categories by combining the metabolic health definitions with normal weight (NW; BMI < 25 kg/m Women classified as MUOW/OB were at higher risk of postmenopausal breast cancer compared to MHNW women considering BMI (OR = 1.58, 95% CI = 1.14-2.19) and WC (OR = 1.51, 95% CI = 1.09-2.08) cut points and there was also a suggestive increased risk for the WHR (OR = 1.29, 95% CI = 0.94-1.77) definition. Conversely, women with the MHOW/OB and MUNW were not at statistically significant elevated risk of postmenopausal breast cancer risk compared to MHNW women. These findings suggest that being overweight or obese and metabolically unhealthy raises risk of postmenopausal breast cancer while overweight or obese women with normal insulin levels are not at higher risk. Additional research should consider the combined utility of anthropometric measures with metabolic parameters in predicting breast cancer risk.
Sections du résumé
BACKGROUND
Excess body fatness and hyperinsulinemia are both associated with an increased risk of postmenopausal breast cancer. However, whether women with high body fatness but normal insulin levels or those with normal body fatness and high levels of insulin are at elevated risk of breast cancer is not known. We investigated the associations of metabolically defined body size and shape phenotypes with the risk of postmenopausal breast cancer in a nested case-control study within the European Prospective Investigation into Cancer and Nutrition.
METHODS
Concentrations of C-peptide-a marker for insulin secretion-were measured at inclusion prior to cancer diagnosis in serum from 610 incident postmenopausal breast cancer cases and 1130 matched controls. C-peptide concentrations among the control participants were used to define metabolically healthy (MH; in first tertile) and metabolically unhealthy (MU; >1st tertile) status. We created four metabolic health/body size phenotype categories by combining the metabolic health definitions with normal weight (NW; BMI < 25 kg/m
RESULTS
Women classified as MUOW/OB were at higher risk of postmenopausal breast cancer compared to MHNW women considering BMI (OR = 1.58, 95% CI = 1.14-2.19) and WC (OR = 1.51, 95% CI = 1.09-2.08) cut points and there was also a suggestive increased risk for the WHR (OR = 1.29, 95% CI = 0.94-1.77) definition. Conversely, women with the MHOW/OB and MUNW were not at statistically significant elevated risk of postmenopausal breast cancer risk compared to MHNW women.
CONCLUSION
These findings suggest that being overweight or obese and metabolically unhealthy raises risk of postmenopausal breast cancer while overweight or obese women with normal insulin levels are not at higher risk. Additional research should consider the combined utility of anthropometric measures with metabolic parameters in predicting breast cancer risk.
Identifiants
pubmed: 37096432
doi: 10.1002/cam4.5896
pmc: PMC10278526
doi:
Substances chimiques
C-Peptide
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
12668-12682Subventions
Organisme : Medical Research Council
ID : MR/M012190/1
Pays : United Kingdom
Informations de copyright
© 2023 World Health Organization; licensed by John Wiley & Sons Ltd. Cancer Medicine published by Wiley Periodicals LLC.
Références
Eur Heart J. 2021 Sep 7;42(34):3388-3403
pubmed: 34333589
Cancer Med. 2023 Jan;12(1):606-618
pubmed: 35719035
J Clin Endocrinol Metab. 2004 Oct;89(10):5013-20
pubmed: 15472199
Crit Rev Clin Lab Sci. 1984;19(4):297-352
pubmed: 6373142
Diabetologia. 1997 Jul;40 Suppl 2:S25-31
pubmed: 9248698
Metabolism. 2019 Mar;92:51-60
pubmed: 30458177
BMJ. 2017 Feb 28;356:j477
pubmed: 28246088
Int J Obes (Lond). 2016 Jan;40(1):153-61
pubmed: 26271188
Asian Pac J Cancer Prev. 2014;15(22):10027-31
pubmed: 25520064
Sci Rep. 2020 Apr 15;10(1):6476
pubmed: 32296103
BMJ. 2022 Jan 18;376:e067516
pubmed: 35042741
PLoS Med. 2016 Apr 05;13(4):e1001988
pubmed: 27046222
Endocr Relat Cancer. 2005 Dec;12(4):1071-82
pubmed: 16322344
Diabetes Care. 2015 Nov;38(11):2177-87
pubmed: 26494809
Int J Cancer. 2018 Aug 1;143(3):543-551
pubmed: 29488210
J Korean Med Sci. 2019 Jan 31;34(6):e49
pubmed: 30787682
J Clin Endocrinol Metab. 2006 Aug;91(8):2906-12
pubmed: 16735483
Cancer Med. 2023 Jun;12(11):12668-12682
pubmed: 37096432
Int J Epidemiol. 1997;26 Suppl 1:S1-5
pubmed: 9126528
Obesity (Silver Spring). 2012 Mar;20(3):651-9
pubmed: 21799477
Obesity (Silver Spring). 2022 Jul;30(7):1323-1334
pubmed: 35785479
J Natl Cancer Inst. 2009 Jan 7;101(1):48-60
pubmed: 19116382
Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):2057-65
pubmed: 25012997
Front Oncol. 2019 Nov 22;9:1290
pubmed: 31824862
J Obes. 2012;2012:460321
pubmed: 23304462
Exp Diabetes Res. 2012;2012:789174
pubmed: 22701472
Cancer Epidemiol Biomarkers Prev. 2021 Mar;30(3):521-528
pubmed: 33277320
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Biol Chem. 2001 Oct 12;276(41):38023-8
pubmed: 11500498
Br J Cancer. 2012 Oct 23;107(9):1608-17
pubmed: 22996614
Lancet Diabetes Endocrinol. 2013 Oct;1(2):152-62
pubmed: 24622321
Int J Cancer. 2006 Aug 1;119(3):659-67
pubmed: 16572422
Cancer Epidemiol Biomarkers Prev. 2017 Dec;26(12):1730-1735
pubmed: 28939589
Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1203-12
pubmed: 22564867
Nutrition. 2022 Apr;96:111590
pubmed: 35180622
Eur J Prev Cardiol. 2016 Jun;23(9):956-66
pubmed: 26701871
N Engl J Med. 2016 Aug 25;375(8):794-8
pubmed: 27557308
Cancer Epidemiol Biomarkers Prev. 2022 Jul 1;31(7):1359-1367
pubmed: 35437568
Int J Cancer. 2009 Dec 1;125(11):2704-10
pubmed: 19588485
Int J Behav Nutr Phys Act. 2008 Jun 02;5:33
pubmed: 18513450
Diabetologia. 2019 Apr;62(4):558-566
pubmed: 30569272
Public Health Nutr. 2002 Dec;5(6B):1113-24
pubmed: 12639222
Int J Epidemiol. 2019 Jun 1;48(3):795-806
pubmed: 30277539
Int J Epidemiol. 1997;26 Suppl 1:S6-14
pubmed: 9126529
Am J Cardiol. 2011 Feb 1;107(3):412-6
pubmed: 21257007
Cancer. 2020 Aug 15;126(16):3638-3647
pubmed: 32530506
Cancer Med. 2022 Feb;11(4):1145-1159
pubmed: 35048536
J Nutr. 2019 Feb 1;149(2):286-294
pubmed: 30590589
Cancer Res. 2015 Jan 15;75(2):270-4
pubmed: 25593034
Int J Cancer. 2000 Dec 1;88(5):828-32
pubmed: 11072255
CMAJ. 2005 May 10;172(10):1301-5
pubmed: 15883404
Cancer Causes Control. 2002 May;13(4):307-16
pubmed: 12074500
Int J Cancer. 2017 Jun 15;140(12):2657-2666
pubmed: 28268252
J Clin Invest. 2019 Oct 1;129(10):3978-3989
pubmed: 31524630
JAMA Netw Open. 2021 May 3;4(5):e218505
pubmed: 33961036
Diabetes Metab Syndr Obes. 2019 Apr 10;12:469-476
pubmed: 31114276